It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Giri stated he is stepping down to pursue new opportunities after careful consideration
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Merck emphasized the broader significance of the findings
Subscribe To Our Newsletter & Stay Updated